期刊
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
卷 59, 期 8, 页码 3028-3032出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/anie.201915896
关键词
anticancer; antitumor agents; drug discovery; heterocyles; inhibitors
资金
- National Natural Science Foundation of China [21738002, 81725020, 81872742]
- National Key R&D Program of China [2017YFA0506000]
- Innovation Program of Shanghai Municipal Education Commission [2019-01-07-00-07-E00073]
As one of the most aggressive and lethal human malignancies with extremely poor prognosis, there is an urgent demand of more effective therapy for the treatment of pancreatic cancer. Reported here is a new, effective therapeutic strategy and the design of small-molecule inhibitors that simultaneously target bromodomain and extra-terminal (BET) and histone deacetylase (HDAC), potentially serving as promising therapeutic agents for pancreatic cancer. A highly potent dual inhibitor (13 a) is identified to possess excellent and balanced activities against BRD4 BD1 (IC50=11 nm) and HDAC1 (IC50=21 nm). Notably, this compound shows higher in vitro and in vivo antitumor potency than the BET inhibitor (+)-JQ1 and the HDAC inhibitor vorinostat, either alone or and in combination, highlighting the advantages of BET/HDAC dual inhibitors for more effective treatment of pancreatic cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据